Theophylline as a Treatment for Children With Pseudohypoparathyroidism Type 1a (Albright Hereditary Osteodystrophy)

Albright Hereditary Osteodystrophy Clinical Trial

Official title:
Effects of Theophylline on cAMP Signaling in Children With Pseudohypoparathyroidism Type 1a

Status Completed

Clinical Trial Summary

This study will test an investigational drug, theophylline, in children with pseudohypoparathyroidism type 1a (PHP1a). This study involves a 3 day visit to the Vanderbilt Clinical Research Center.

Clinical Trial Description

Study measures will be done at baseline and during a 24h infusion of IV theophylline. Theophylline levels will be drawn to ensure therapeutic dosing and to monitor for toxicity. Measures include laboratory values, response to PTH infusion and resting energy expenditure. ;

Study Design

Related Conditions & MeSH terms

Albright Hereditary Osteodystrophy
Pseudohypoparathyroidism
Pseudohypoparathyroidism Type 1a

Clinical Trial Details

NCT number	NCT02463409
Study type	Interventional
Source	Vanderbilt University Medical Center
Contact
Status	Completed
Phase	Phase 2
Start date	June 2015
Completion date	October 2016

View Details

See also
Status	Clinical Trial	Phase
Recruiting	`NCT03029429` - Theophylline Treatment for Pseudohypoparathyroidism	Phase 2
Enrolling by invitation	`NCT04240821` - Theophylline for Treatment of Pseudohypoparathyroidism	Phase 2
Terminated	`NCT01398774` - Energy Expenditure and Body Composition in Pseudohypoparathyroidism 1a
Terminated	`NCT03761290` - Glucose Homeostasis in Pseudohypoparathyroidism
Recruiting	`NCT04551170` - Theophylline Treatment for Pseudohypoparathyroidism - Children 2-12 Years Old	Phase 2
Recruiting	`NCT00209235` - Albright Hereditary Osteodystrophy: Natural History, Growth, and Cognitive/Behavioral Assessments	N/A
Completed	`NCT02411461` - Early-onset Obesity and Cognitive Impairment in Children With Pseudohypoparathyroidism